Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft.
Sustained delivery of anti-proliferative drugs to the perivascular area using an injectable polymeric platform is a strategy to inhibit vascular hyperplasia and stenosis. In this study, the concentrations of sirolimus in vascular tissues were evaluated after delivery using an injectable platform made of poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA). In order to optimize the drug release profile, the effect of two solvents or solid loading of the sirolimus into the polymer gel was first examined in vitro. The early release was slower with loading of dry drug into the polymer, compared to drug dissolution in solvents. Dry sirolimus was therefore used to load the polymer and applied to the perivascular surface of the graft-venous anastomosis at the time of surgical placement of a carotid-jugular synthetic hemodialysis graft in a porcine model. This was replenished by ultrasound-guided injection of additional drug-laden polymer at one, two and three weeks post-operatively. Magnetic resonance imaging (MRI) using pulse sequences specifically designed for optimal detection of the polymeric gel showed that the polymer injected post-operatively remained at the juxta-anastomotic perivascular site at two weeks. Sirolimus was extracted from various segments of the juxta-anastomotic tissues and the drug concentrations were determined using HPLC MS/MS. Tissue sirolimus concentrations at one and two weeks were highest near the venous anastomosis, which were approximately 100- to 500-fold greater than the concentrations necessary to inhibit vascular smooth muscle cell proliferation in vitro. Drug concentrations remained above the inhibitory concentrations for at least six weeks post-operatively. Thus, serial injections of sustained-delivery polymer gel loaded with sirolimus can provide high localized concentrations at target vascular tissues and thus may be useful for the prevention and treatment of vascular proliferative disorders such as hemodialysis graft stenosis. In addition, MRI is useful for the monitoring of the location of the drug depot.
Owen
Shawn C
SC
Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, 301 Skaggs Hall, 30 South 2000 East, Salt Lake City, UT 84112, USA.
Li
Huan
H
Sanders
William G
WG
Cheung
Alfred K
AK
Terry
Christi M
CM
D000818:Animals; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D017536:Carotid Artery, Common / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D049109:Cell Proliferation / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding; D005782:Gels; D006083:Graft Occlusion, Vascular / Q000473:pathology / Q000517:prevention & control*; D007601:Jugular Veins / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D016014:Linear Models; D018810:Magnetic Resonance Angiography; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry*; D011098:Polyglactin 910 / Q000008:administration & dosage / Q000737:chemistry*; D020123:Sirolimus / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012995:Solubility; D034421:Sus scrofa; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005782:Gels; C528571:poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid); D011098:Polyglactin 910; D011092:Polyethylene Glycols; D020123:Sirolimus
Xenotransplantation. 2008 Nov-Dec;15(6):407-16
19152669
Biomaterials. 2005 Sep;26(26):5386-94
15814137
Ther Drug Monit. 2000 Oct;22(5):608-12
11034268
Kidney Int. 2008 Nov;74(10):1247-61
18668026
Gastrointest Endosc. 2007 Mar;65(3):448-53
17173909
Vasc Health Risk Manag. 2005;1(1):73-8
17319099
Kidney Int. 2004 Nov;66(5):2061-9
15496180
Adv Drug Deliv Rev. 2002 Jan 17;54(1):3-12
11755703
Nat Protoc. 2009;4(4):526-34
19325549
Anticancer Drugs. 2009 Feb;20(2):89-95
19209024
Surgery. 1983 Sep;94(3):464-70
6612581
Transplant Proc. 2008 Dec;40(10):3623-6
19100454
Clin Exp Rheumatol. 2009 Mar-Apr;27(2):201-7
19473558
Am Heart J. 1990 May;119(5):1164-84
2330873
Blood Purif. 2006;24(3):289-98
16465049
J Control Release. 2009 Jul 1;137(1):20-4
19285530
J Biomed Mater Res A. 2009 Nov;91(2):408-15
18985789
Acta Biomater. 2005 Nov;1(6):597-606
16701840
Circulation. 1996 Oct 1;94(7):1655-64
8840858
J Control Release. 2008 May 8;127(3):189-207
18321604
Clin Transplant. 2000 Apr;14(2):97-109
10770413
Biomaterials. 2008 Aug;29(22):3213-20
18455787
Anticancer Drugs. 2007 Mar;18(3):283-9
17264760
J Biomed Mater Res A. 2009 Dec 15;91(4):1111-8
19107794
Adv Drug Deliv Rev. 2002 Jan 17;54(1):37-51
11755705
Circulation. 2001 Oct 2;104(14):1591-3
11581133
Clin Chem. 2002 Jun;48(6 Pt 1):955-8
12029019
Adv Drug Deliv Rev. 2009 Aug 10;61(10):785-94
19422870
Tissue Eng Part A. 2009 Apr;15(4):923-33
19061427
Semin Dial. 2008 Nov-Dec;21(6):522-7
19000123
Heart. 2007 Aug;93(8):922-7
17449502
Pharm Res. 2006 Apr;23(4):718-28
16552498
Cardiovasc Res. 2005 Dec 1;68(3):415-24
16023630
Nephrol Dial Transplant. 2008 Feb;23(2):525-33
18037619
Clin Chem Lab Med. 2008;46(11):1631-4
18842108
Ann Surg. 1985 Aug;202(2):235-9
4015229
J Biomed Mater Res B Appl Biomater. 2006 Apr;77(1):135-43
16206204
Pharm Res. 2009 Jul;26(7):1739-44
19384466
Circulation. 1996 Jun 15;93(12):2178-87
8925587
Kidney Int. 2006 Jun;69(12):2179-85
16672912
J Control Release. 2001 May 14;72(1-3):203-15
11389999
J Vasc Surg. 2006 Sep;44(3):633-41
16950446
Free Radic Biol Med. 2008 Jan 1;44(1):73-81
18045549
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4840-6
19324846
J Mass Spectrom. 2007 Jun;42(6):793-802
17511017